This research measured the antitumor activity of EGF-IGF-LDP-AE on NSCLC, and compared the potency of bispecific fusion protein with lidamycin and its monospecific counterparts, EGF-LDP-AE and LDP-IGF-AE. Here, IGF1 is linked to non-small cell lung carcinoma.